Occam Places Paul Audhya as CMO of KalVista

Occam Places Paul Audhya as CMO of KalVista

KalVista Pharmaceuticals is a public pharmaceutical company which has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

In May 2021 Occam placed Paul Audhya, MD as its CMO. Audhya has over 20 years of clinical development and global medical affairs leadership experience. He previously served as Senior Vice President, Global Medical Affairs at Arena Pharmaceuticals. Prior to Arena, Dr. Audhya held positions of increasing responsibility across all stages of drug development at Vertex Pharmaceuticals, Hospira, Reata Pharmaceuticals, Abbott Labs, Amgen, Bristol Myers Squibb and Janssen.

About Occam Global

Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.